A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.
AffiliationCentre for Colorectal Disease, St. Vincent's University Hospital, Dublin,, Ireland. email@example.com
Adrenal Cortex Hormones/therapeutic use
Aged, 80 and over
Antibodies, Monoclonal/therapeutic use
Crohn Disease/*drug therapy/*surgery
*Guidelines as Topic
Immunologic Factors/therapeutic use
Severity of Illness Index
MetadataShow full item record
CitationClin Gastroenterol Hepatol. 2009 Mar;7(3):323-8; quiz 252. Epub 2008 Oct 30.
JournalClinical gastroenterology and hepatology : the official clinical practice journal, of the American Gastroenterological Association
AbstractBACKGROUND & AIMS: Therapeutic strategies for patients with Crohn's disease are based on American and European guidelines. High rates of corticosteroid dependency and low remission rates are identified as weaknesses of this therapy and as justification for early introduction of biologic agents (top-down treatment) in moderate/severe Crohn's disease. We reviewed outcomes and corticosteroid-dependency rates of patients with moderate-to-severe disease who were treated according to the international guidelines. METHODS: Consecutive patients (102) newly diagnosed with Crohn's disease in 2000-2002 were identified from a prospectively maintained database. Severity of disease was scored using the Harvey-Bradshaw Index (HBI). Disease was classified by Montreal classification. Five-year follow-up data were recorded. RESULTS: Seventy-two patients had moderate/severe disease at diagnosis (HBI >8). Fifty-four (75%) had nonstricturing, nonpenetrating disease (B1). Sixty-four (89%) received corticosteroids, and 44 (61%) received immunomodulators. Twenty-one patients (29%) received infliximab. Thirty-nine patients (54%) required resection surgery. At a median of 5 years, 66 of 72 (92%) patients with moderate/severe disease were in remission (median HBI, 1). Twenty-five patients (35%) required neither surgery nor biologic therapy. CONCLUSIONS: When international treatment guidelines are strictly followed, Crohn's disease patients can achieve high rates of remission and low rates of morbidity at 5 years. Indiscriminate use of biologic agents therefore is not appropriate for all patients with moderate-to-severe disease.
- Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
- Authors: Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD
- Issue date: 2006 Dec
- Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.
- Authors: Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, Pfefferkorn M, Mezoff A, Rosh J, Tolia V, Otley A, Griffiths A, Moyer MS, Oliva-Hemker M, Wyllie R, Rothbaum R, Bousvaros A, Del Rosario JF, Hale S, Lerer T, Pediatric IBD Collaborative Research Group.
- Issue date: 2006 Sep
- Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
- Authors: Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research Group., North-Holland Gut Club.
- Issue date: 2010 Feb
- Infliximab in Crohn's disease: early and long-term treatment.
- Authors: Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A
- Issue date: 2008 Jul
- Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
- Authors: Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
- Issue date: 2007 Mar